Huihe Biotechnology (Shanghai) Co., Ltd. announced that it has raised CNY 100 million in funding led by new investors Shanghai Prosperico Ventures Co., Ltd., Jolmo Investment Management Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Hangzhou Tailong Venture Capital Partnership Enterprise (L.P.) and Shenzhen Capital Group Co., Ltd. on May 15, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
52.63 CNY | -1.37% | -3.70% | +0.53% |
22/04 | Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
18/03 | China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6% | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.53% | 2.95B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-5.78% | 13.3B | |
-11.38% | 11.65B | |
-49.84% | 10.12B | |
+5.24% | 9.06B |
- Stock Market
- Equities
- 688278 Stock
- News Xiamen Amoytop Biotech Co., Ltd.
- Huihe Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shanghai Prosperico Ventures Co., Ltd., Shenzhen Capital Group Co., Ltd., Jolmo Investment Management Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Hangzhou Tailong Venture Capital Partnership Enterprise (L.P.)